NPPA suggests expanding the list of essential medicines whose prices are controlled

Sun maintained it would retain the best of both organisations to build a global pharma company.

US country head, key departmental heads leave; more likely to follow.

No Ebola case detected in the country so far; experts say a robust preparedness plan to fight the virus missing.

Currently, the govt directly caps prices of 348 formulations at the average price of all medicines in a particular segment with at least 1% market share

Among the companies likely to sign deals with Gilead are Cadila, Hetero, Strides Arcolab and Mylan, while Cipla is expected to earn active pharmaceutical ingredient rights.

It hopes to turn around Ranbaxy within four years of closing the deal by improving efficiency and resolving all regulatory issues

The idea is to keep a close watch on real-time price movements, the maximum retail price of medicines and their availability.

Ministerial consultations on, with recognition of the potential, and the need to not classify it under the same rules as for pharmaceuticals.

Slapped with Rs 242-crore fine by US authorities for rule violations at Toansa unit, say sources; 2nd such hefty rap in the recent past from US regulators for bending rules.

Altaf Ahmed Lal, country head of the US Food and Drug Administration (US FDA) in India, has quit and so have a few other key officials at the American drug regulator's India office.

Sun-Ranbaxy are keen to complete the merger process.

In a letter to health minister Harsh Vardhan, the Indian Pharmaceutical Alliance, an industry body representing leading pharma companies, including Sun Pharma, Lupin, Dr Reddy's Labs, Cadila Health and Glenmark, stressed the need for an out-of-court settlement with health activists fighting for the rights of clinical trial participants.

The Drug (Prices Control) Order implemented in May last year brought into its purview 652 packs of 348 formulations.

The company did not respond to specific queries on the project's expansion.

Even smaller companies like Torrent Pharma and Alembic file five to 10 ANDAs every year.

Experts say despite it being a global deal, the transaction will have to undergo CCI scrutiny because of the scale of operations.

On Tuesday, Novartis agreed to buy GSK's oncology products business for $14.5 billion, while selling its vaccines business, excluding flu, to GSK for $7.1 billion.

ICAI has also imposed a fine of Rs 5 lakh on each of the three accused in Satyam case.

The company buys distressed assets across the globe and turns them around to not only add to its books but also its product pipeline and regions.